AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30729945
Drug: Laser‐activated irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser‐activated irrigation (LAI) with no solution
Trial: 28467859
Drug: Bambuterol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bambuterol (20 mg)
Trial: 28467859
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of theophylline and bambuterol
Trial: 23938173
Drug: Modafinil (50-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (50-200 mg/day)
Trial: 16634542
Drug: Org 9426
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 9426 0.3 mg x kg(‐1)
Trial: 16634542
Drug: Org 9426
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 9426 0.6 mg x kg(‐1)
Trial: 16634542
Drug: Org 9426
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 9426 0.9 mg x kg(‐1)
Trial: 12738151
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 400 micro g, followed by two doses of oral misoprostol 100 micro g 4 hours apart (Group 2)
Trial: 12738151
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of oxytocin 10 IU plus oral misoprostol 400 micro g, followed by two doses of oral misoprostol 100 micro g 4 hours apart (Group 1)
Trial: 12738151
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of oxytocin 10 IU plus intramuscular administration of methylergonovine maleate 0.2 mg (Group 4)
Trial: 8857441
Drug: Dopexamine infusion
RxNorm normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopexamine infusion at a dose of 2 microg kg-1 min-1, titrated to achieve normal blood pressure, urine output, and base deficit.
Trial: 1507375
Drug: Aspirin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (two 325‐mg tablets once per day)
Trial: 31432311
Drug: Sodium hypochlorite
RxNorm normalized name: Sodium hypochlorite
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium hypochlorite gel
Trial: 28259320
Drug: Amoxicillin 500
RxNorm normalized name: amoxicillin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500 MG plus Metronidazole 500 MG 3 times a day for 3 or 7 days
Trial: 27006286
Drug: Midazolam (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (low dose)
Trial: 24927970
Drug: Trimetazidine (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (70 mg/day for 72 hours)
Trial: 19071066
Drug: Standard diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diet and behavioral therapy (stimulation off)
Trial: 17214729
Drug: Allylamine-benzoyl peroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allylamine-benzoyl peroxide combination therapy
Trial: 17214729
Drug: Proactiv Solution
RxNorm normalized name: Proactiv Solution Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactiv Solution (benzoyl peroxide alone)
Trial: 9231212
Drug: artemisinin suppositories
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: artemisinin suppositories followed by mefloquine
Trial: 9231212
Drug: intramuscular artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intramuscular artesunate followed by mefloquine
Trial: 9231212
Drug: intravenous quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous quinine followed by pyrimethamine/sulfadoxine
Trial: 8094279
Drug: Weekly alternating
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly alternating zidovudine (200 mg every 4 hours) and ddC (0.03 mg/kg every 4 hours)
Trial: 8094279
Drug: Weekly intermittent
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly intermittent zidovudine (200 mg every 4 hours)
Trial: 8094279
Drug: Continuous zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous zidovudine therapy
Trial: 8094279
Drug: Alternating therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating therapy with zidovudine and ddC
Trial: 8094279
Drug: Alternating therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating therapy limbs
Trial: 7496696
Drug: Iodixanol 270
RxNorm normalized name: IODIXANOL 270mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol 270 mgI ml‐1
Trial: 7496696
Drug: Iopamidol 300
RxNorm normalized name: iopamidol 300 mg iodine/mL (61 %) INTRAVEN KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopamidol 300 mgI ml‐1
Trial: 1675534
Drug: Topical meclocycline
RxNorm normalized name: meclocycline Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical meclocycline sulfosalicylate
Trial: 1675534
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (topical meclocycline sulfosalicylate and benzoyl peroxide)
Trial: 31412895
Drug: Standard TB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard TB therapy (for HIV-positive patients)
Trial: 31412895
Drug: Standard TB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard TB therapy (for HIV-negative patients)
Trial: 31412895
Drug: Standard TB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard TB therapy (for both groups)
Trial: 22463733
Drug: Directed home
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directed home medicines review service
Trial: 20049950
Drug: pH-dependent release
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH-dependent release formulation 3.6 g/day
Trial: 20049950
Drug: pH-dependent release
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH-dependent release formulation 2.4 g/day
Trial: 20049950
Drug: Time-dependent release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-dependent release formulation 2.25 g/day
Trial: 20049950
Drug: pH-dependent release
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH-dependent release formulations (2.4 g and 3.6 g)
Trial: 18411384
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin therapy using glargine self-titrated according to a patient algorithm
Trial: 18411384
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy with physician-adjusted doses of oral agents
Trial: 397711
Drug: Nefopam 15
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 15 mg (maximum 90 mg)
Trial: 397711
Drug: Oxycodone 4
RxNorm normalized name: OXYCODONE 4.88MG/ASA 325MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 4 mg (maximum 24 mg)
Trial: 6287928
Drug: Intranasal enviroxime
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal enviroxime (one spray per nostril, five times per day)
Trial: 6287928
Drug: Intranasal enviroxime
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal enviroxime
Trial: 31237727
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg risankizumab
Trial: 26171754
Drug: Video consultation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Video consultation during monthly home visits
Trial: 26171754
Drug: Regular monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular monthly home visits (no video consultation)
Trial: 22304676
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment groups (post-treatment and 1-month follow-up)
Trial: 22304676
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment groups (1-month follow-up)
Trial: 12365197
Drug: Diphenhydramine 120
RxNorm normalized name: pseudoephed/diphenhydramine 120 mg-100 mg ORAL TABLET, EXTENDED RELEASE 12 HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 120 mg
Trial: 10421239
Drug: Pramlintide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide (30 microg four times daily)
Trial: 2264198
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with the BCG vaccine (Group 2)
Trial: 2264198
Drug: Levamisole for
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole for immunotherapy (Group 3)
Trial: 2264198
Drug: Combined method:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined method: BCG vaccine, placental suspension, and cyclophosphamide (Group 4)
Trial: 28869573
Drug: LEU (L-leucine)
RxNorm normalized name: Leu
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LEU (L-leucine)
Trial: 21365629
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Lonafarnib (LNF) and Docetaxel (DTX)
Trial: 17522596
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch (5-20 cm2)
Trial: 17522596
Drug: Rivastigmine capsules
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine capsules (1.5-6 mg Q12H, i.e., 3-12 mg/day)
Trial: 16440148
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) administered intravenously during the operation
Trial: 10891820
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (1 mg/m²/d) for 24 months
Trial: 31570179
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg L-DOPA
Trial: 26088460
Drug: Pre-RT temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-RT temozolomide followed by concurrent temozolomide and radiotherapy (RT)
Trial: 26088460
Drug: Pre-RT temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-RT temozolomide followed by concurrent temozolomide and RT
Trial: 26088460
Drug: Pre-RT temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-RT temozolomide followed by concurrent temozolomide and RT in codeleted patients
Trial: 26088460
Drug: Pre-RT temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-RT temozolomide followed by concurrent temozolomide and RT in non-codeleted patients
Trial: 20226502
Drug: Weekly irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly irinotecan (Iri) 35 mg/m(2) and cisplatin (CP) 20 mg/m(2) with 45‐Gy pelvic irradiation
Trial: 19213341
Drug: Integrative medical
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrative medical treatment plus prednisone
Trial: 16860509
Drug: Warfarin plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin plasma concentration monitoring
Trial: 16860509
Drug: Warfarin dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin dosage and concentration correlation with INR
Trial: 6314747
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 micrograms/kg bolus followed by 5 micrograms/kg/h infusion)
Trial: 29940217
Drug: BNX-RDT 11.4/2.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNX-RDT 11.4/2.9 mg
Trial: 29940217
Drug: BNX-RDT 2.9/0.71
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNX-RDT 2.9/0.71 mg
Trial: 21962726
Drug: Buprenorphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine treatment (BT)
Trial: 1553897
Drug: Regimen A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A: metoclopramide [2 mg/kg x 4 i.v.] + methylprednisolone (250 mg x 2 i.v.) + diphenhydramine (50 mg x 2 i.v.)
Trial: 1553897
Drug: Regimen B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B: metoclopramide (3 mg/kg x 2 i.v.) + dexamethasone (20 mg i.v.) + diphenhydramine (50 mg i.v.)
Trial: 18312768
Drug: Combined simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined simvastatin and ezetimibe treatment
Trial: 20501862
Drug: Isotretinoin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (30 mg/d for 3 years)
Trial: 16538734
Drug: Iodized salt
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodized salt with iodine concentration of 6 +/- 2 mg/kg
Trial: 16538734
Drug: Iodized salt
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodized salt with iodine concentration of 15 +/- 2 mg/kg
Trial: 16538734
Drug: Iodized salt
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodized salt with iodine concentration of 24 +/- 2 mg/kg
Trial: 16538734
Drug: Iodized salt
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodized salt with iodine concentration of 34 +/- 2 mg/kg
Trial: 12434280
Drug: Cisplatin/epinephrine gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/epinephrine gel
Trial: 3046638
Drug: Interferon alfa-n1
RxNorm normalized name: interferon alfa-n1
DrugBank: Interferon alfa-n1 (DB00011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa-n1 (Wellferon) intramuscularly at a dosage of 5 megaunits per square meter daily for 28 days and then thrice weekly for five months
Trial: 30526678
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg (TNFi-naïve)
Trial: 30526678
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg (TNFi-naïve)
Trial: 30526678
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg (TNFi-experienced)
Trial: 30526678
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg (TNFi-experienced)
Trial: 28356129
Drug: 6 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/d probiotic
Trial: 28356129
Drug: 6 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/d synbiotic
Trial: 20587582
Drug: Persistent TSH-suppressive
RxNorm normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Persistent TSH-suppressive l-T4 substitution (low-TSH group)
Trial: 19431244
Drug: Cortexin, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortexin, 20 mg daily for 10 days
Trial: 19431244
Drug: Placebo, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 20 mg daily for 10 days
Trial: 31674202
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement containing cranberry, D-mannose and anti-inflammatory molecules, taken twice a day for 2 weeks starting from surgery
Trial: 20694783
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicines administered according to syndrome typing for oral intake and external washing
Trial: 20694783
Drug: Glucosamine hydrochloride
RxNorm normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine hydrochloride and Celecoxib, combined with intra-articular injection of sodium hyaluronate and peri-articular pain spot blocking with Triamcinolone Acetonaide Acetate injection
Trial: 12859160
Drug: Ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5 mg daily)
Trial: 1681917
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g plus metronidazole 1.5 g once daily (n = 94)
Trial: 1681917
Drug: Ampicillin 2
RxNorm normalized name: ampicillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin 2 g plus netilmicin 150 mg twice daily plus metronidazole 1.5 g once daily (n = 96)
Trial: 7023519
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 0.02 mg kg‐1
Trial: 7023519
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 0.2 mg kg‐1
Trial: 24637941
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg t.i.d. sorafenib
Trial: 24637941
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg b.i.d. sorafenib
Trial: 18094220
Drug: darunavir/ritonavir 400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/ritonavir 400/100 mg bid
Trial: 18094220
Drug: darunavir/ritonavir 400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/ritonavir 400/100 mg bid plus clarithromycin 500 mg bid
Trial: 16801665
Drug: Analogous therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analogous therapy in a patient with non‐CNS lymphoma
Trial: 8624887
Drug: Sublingual nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual nifedipine 5 mg, repeated after 15 minutes if DBP > 120 mmHg
Trial: 8624887
Drug: Intravenous hydrallazine
RxNorm normalized name: Hydrallazine
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous hydrallazine 5 mg, repeated after 15 minutes if DBP > 120 mmHg
Trial: 1419549
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg cephradine 12-hourly for seven days
Trial: 1419549
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg cefuroxime axetil 12-hourly for seven days
Trial: 3973648
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) alone, 600 mg/m2 IV once weekly
Trial: 3973648
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) plus radiation therapy, 4,000 rad, with adjuvant 5-FU, 600 mg/m2 IV for the first three days of radiotherapy, then maintenance 5-FU, 600 mg/m2 weekly
Trial: 3973648
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) plus radiation therapy
Trial: 28647736
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg of vitamin D3 supplementation daily
Trial: 28647736
Drug: 30 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 µg of vitamin D3 supplementation daily
Trial: 28647736
Drug: Both 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 10 µg and 30 µg of vitamin D3 supplementation
Trial: 22013143
Drug: PGF2α (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGF2α (3.5 µg/kg/min over 20 min)
Trial: 19485589
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) with minimal parent involvement
Trial: 19485589
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) with active parent involvement
Trial: 1552888
Drug: Cefotiam (CTM-L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotiam (CTM-L group)
Trial: 3553480
Drug: 1500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg/day elemental calcium for 4 weeks
Trial: 24899709
Drug: Resveratrol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (200 mg/d)
Trial: 22939758
Drug: High-dose grass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose grass pollen SLIT
Trial: 18337059
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (GT) 2 g of leaves in 200 mL of water, three times per day for 7 days